Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Angelo Famà(Azienda Sanitaria Unità Locale di Reggio Emilia), James R. Cerhan(Mayo Clinic), Thomas M. Habermann(Mayo Clinic in Arizona), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Jonathan W. Friedberg(University of Rochester), Peter Martin(Northwestern University), Izidore S. Lossos(University of Miami), Matthew J. Maurer(Mayo Clinic in Arizona), Carla Casulo(University of Rochester Medical Center), Susan L. Slager(Mayo Clinic), Brad S. Kahl(UW Health University Hospital), David L. Jaye(Emory University), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Brian K. Link(University of Iowa), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Andrew L. Feldman(Mayo Clinic in Arizona), Umar Farooq(Wake Forest University), Jonathon B. Cohen(Emory University), Cristine Allmer(Mayo Clinic in Arizona), Carrie A. Thompson(Mayo Clinic)
Cited by 13
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k